Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002044662 | SCV002116236 | uncertain significance | Familial aplasia of the vermis; Meckel-Gruber syndrome | 2021-11-20 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 706 of the RPGRIP1L protein (p.Lys706Asn). This variant is present in population databases (rs759934290, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with RPGRIP1L-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002489938 | SCV002780457 | uncertain significance | Joubert syndrome 7; Meckel syndrome, type 5; COACH syndrome 3 | 2021-12-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003247047 | SCV003982587 | uncertain significance | Inborn genetic diseases | 2023-05-05 | criteria provided, single submitter | clinical testing | The c.2118A>C (p.K706N) alteration is located in exon 15 (coding exon 14) of the RPGRIP1L gene. This alteration results from a A to C substitution at nucleotide position 2118, causing the lysine (K) at amino acid position 706 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |